Gadolinium-based contrast agents (GBCAs) are widely used in MRI to enhance image clarity, but they carry potential risks, particularly for patients with impaired kidney function, due to their association with nephrogenic systemic fibrosis (NSF). Recent advancements and guidelines emphasize the importance of using the lowest effective dose and choosing macrocyclic GBCAs to mitigate these risks while still achieving diagnostic efficacy.